CN216469406U - Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) - Google Patents
Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) Download PDFInfo
- Publication number
- CN216469406U CN216469406U CN202122354519.8U CN202122354519U CN216469406U CN 216469406 U CN216469406 U CN 216469406U CN 202122354519 U CN202122354519 U CN 202122354519U CN 216469406 U CN216469406 U CN 216469406U
- Authority
- CN
- China
- Prior art keywords
- hrm
- placing
- transcription factor
- screening
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 41
- 238000012216 screening Methods 0.000 title claims abstract description 39
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 28
- 102100031690 Erythroid transcription factor Human genes 0.000 title claims abstract description 18
- 101710100588 Erythroid transcription factor Proteins 0.000 title claims abstract description 18
- 238000002844 melting Methods 0.000 title claims abstract description 12
- 230000008018 melting Effects 0.000 title claims abstract description 12
- 108010089558 erythroid Kruppel-like factor Proteins 0.000 title claims description 46
- 102100022248 Krueppel-like factor 1 Human genes 0.000 title claims description 22
- 108090000623 proteins and genes Proteins 0.000 title description 9
- 102000004169 proteins and genes Human genes 0.000 title description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 66
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 31
- 238000003908 quality control method Methods 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 238000007789 sealing Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000002390 adhesive tape Substances 0.000 claims description 5
- 239000003507 refrigerant Substances 0.000 claims description 5
- 238000009434 installation Methods 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 230000035772 mutation Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000007480 sanger sequencing Methods 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101001046587 Homo sapiens Krueppel-like factor 1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The utility model discloses a detection kit for screening gene mutation of an erythroid transcription factor EKLF (extracellular killer tumor necrosis factor) by using HRM (high resolution melting), which comprises the following components: the box body is provided with an accommodating cavity; the cover body is used for sealing the box body and can be opened and closed relative to the box body; the buffer frame is accommodated in the accommodating cavity, the height of the box body is higher than that of the buffer frame, the buffer frame forms 3 different height placing areas which are respectively a first placing area, a second placing area and a third placing area, and the first placing area, the second placing area and the third placing area are respectively used for placing an upstream primer pair reagent tube, a downstream primer pair reagent tube, a PCR premixed liquid reagent tube and a negative quality control product reagent tube. The detection kit for screening the gene mutation of the erythroid transcription factor EKLF by using the HRM has the advantage of convenience in detection.
Description
Technical Field
The utility model relates to the technical field of biological detection, in particular to a detection kit for screening gene mutation of an erythroid transcription factor EKLF (extended high-resolution fluorescence) by using HRM (high-resolution melting).
Background
The erythroid transcription factor EKLF/KLF1 was first discovered by Bieker, scientist of the West Neissan medical institute, and regulates a series of growth and development processes of erythrocytes by specifically recognizing and combining with a conserved DNA sequence to start transcription of downstream genes. The EKLF gene (NC-000019.10) is located at 19p13.2, has a full length of 2781bp, comprises three exons, two introns and a protein consisting of 2 functional domains, and one is located at the N end and is a transcription activation structural domain enriched by proline; the other, located at the C-terminus, is a zinc finger domain that binds to a conserved DNA sequence. Studies have shown that dominant or double mutations in the EKLF gene can lead to a range of hematological phenotypes, while single-allelic mutations in the EKLF gene can lead to a range of benign phenotypes, such as fetal hemoglobin HbF and adult hemoglobin A2(HbA2) And the like, thereby generating a phenotype modification effect on the clinical phenotype of the beta-thalassemia.
The method for screening unknown gene mutation mainly comprises methods such as Denaturing High Performance Liquid Chromatography (DHPLC), single-strand conformation polymorphism (SSCP), Sanger sequencing method (gold standard), next-generation sequencing and the like. However, the detection methods have the defects of complicated operation steps, long detection period, high detection cost and the like.
High resolution melting profiling (HRM) technology is a genetic analysis method that can achieve mutation scanning and genotyping with High throughput and reliable results. The main principle of HRM mutation screening is that according to the fragment length, GC content and base complementary pairing difference of different nucleic acid molecules, when a PCR product is heated and denatured, even if the change of a single base is enough to influence the fragment, the melting temperature (Tm value) is different, double-stranded DNA molecules simultaneously form the shape and position of a unique melting curve, so that samples are distinguished according to the difference of the melting curves, and finally Sanger sequencing confirmation is carried out on a screened mutation positive sample.
Therefore, the HRM has important application value in screening EKLF gene mutation, and the current screening method is the Sanger sequencing method most commonly. However, the experiment needs to be performed step by step, the required reagent is complex, time-consuming and labor-consuming, the economic cost is high, and the method is not suitable for large-scale population screening, so that a detection kit suitable for large-scale population screening of the EKLF gene mutation is needed to be designed.
SUMMERY OF THE UTILITY MODEL
The present invention is directed to solving at least one of the problems of the prior art. Therefore, the utility model provides a detection kit for screening the gene mutation of the red transcription factor EKLF by using HRM, which can conveniently carry out detection.
According to the first aspect of the utility model, the detection kit for screening the gene mutation of the erythroid transcription factor EKLF by using HRM comprises: the box body is provided with an accommodating cavity; the cover body is used for sealing the box body and can be opened and closed relative to the box body; the buffer frame, accept in accept the intracavity, just the height of box body is higher than the height of buffer frame, the buffer frame forms 3 high diverse and places the district, is first to place the district, the second is placed the district and the third is placed the district respectively, first place the district the second is placed the district with the third is placed the district and is used for placing upstream and downstream primer pair reagent pipe, PCR reaction premix liquid reagent pipe and negative quality control article reagent pipe respectively.
The detection kit for screening the gene mutation of the red transcription factor EKLF by applying the HRM provided by the embodiment of the utility model at least has the following beneficial effects: through setting up the buffer frame and setting up the region of placing of three high difference, respectively be used for placing upstream and downstream primer pair reagent pipe, PCR reaction mixes liquid reagent pipe and negative quality control article reagent pipe in advance, thereby integrate all reagents of screening EKLF gene mutation in a box body, and the high diverse in the region that different types of test solution placed, can make things convenient for medical personnel to distinguish fast and the operation of taking, thereby quick detecting, cushion each reagent pipe through setting up the buffer frame, the convenience is protected the reagent pipe in the transportation.
According to some embodiments of the utility model, the total volume of the placed PCR reaction premix in the PCR reaction premix reagent tube is 1mL, and the PCR reaction premix components comprise 10 XPCR buffer, 2.5nM dNTPs, 5U/. mu.l Taq DNA polymerase, 1 XPLC Green, 5M Betain, deionized water and DMSO.
According to some embodiments of the utility model, the kit comprises 9 upstream primer pair reagent tubes, each of the upstream primer pair reagent tubes contains an upstream primer pair and a downstream primer pair, and 9 pairs of the upstream primer pair and the downstream primer pair cover a promoter region of the EKLF gene, an exon region of the EKLF gene and a 3' UTR region of the EKLF gene.
According to some embodiments of the utility model, the concentration of the upstream and downstream primer pair is 10 μ M.
According to some embodiments of the utility model, the middle part of the buffer frame forms a mounting cavity, and the cooling object is arranged in the mounting cavity.
According to some embodiments of the present invention, the first placement region is provided with a first placement hole in a height direction of the cartridge body, the upstream and downstream primer pair reagent vessels being inserted into the first placement hole; the second placing area is provided with a second placing hole along the height direction of the box body, and the PCR reaction premixed liquid reagent tube is inserted into the second placing hole; and a third placing hole is formed in the third placing area along the height direction of the box body, and the negative quality control product reagent tube is inserted into the third placing hole.
According to some embodiments of the utility model, the first placement hole, the second placement hole and the third placement hole are all in communication with the mounting cavity.
According to some embodiments of the utility model, the buffer frame comprises a base and a fixed seat, the base is provided with a placing groove, the fixed seat is arranged on the top of the base, the fixed seat forms the placing areas, and the fixed seat and the base are arranged in an enclosing manner to form the installation cavity.
According to some embodiments of the utility model, the base is made of foam and the holder is made of sponge.
According to some embodiments of the utility model, the edge of the inner surface of the cover is provided with an adhesive tape and the cover is provided with a tear strip.
Additional aspects and advantages of the utility model will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the utility model.
Drawings
The utility model is further described with reference to the following figures and examples, in which:
FIG. 1 is a schematic structural diagram of a detection kit for screening an erythroid transcription factor EKLF gene mutation by using HRM according to an embodiment of the present invention;
fig. 2 is a schematic structural view of the fixing base in fig. 1.
Reference numerals:
a detection kit 100 for screening gene mutation of an erythroid transcription factor EKLF by using HRM;
a box body 110 and a containing cavity 111;
the cover body 120, the adhesive tape 121, the tear tape 122 and the two-dimensional code 123;
the buffer frame 130, the first placing area 131, the first placing hole 1311, the second placing area 132, the second placing hole 1321, the third placing area 133, the third placing hole 1331, the mounting cavity 134, the base 135, and the fixing seat 136;
an upstream and downstream primer pair reagent tube 140;
a PCR reaction premix reagent tube 150;
a negative quality control material reagent tube 160;
a refrigerant 170.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to the same or similar elements or elements having the same or similar function throughout. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention.
In the description of the present invention, it should be understood that the orientation or positional relationship referred to in the description of the orientation, such as the upper, lower, front, rear, left, right, etc., is based on the orientation or positional relationship shown in the drawings, and is only for convenience of description and simplification of description, and does not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus, should not be construed as limiting the present invention.
In the description of the present invention, the meaning of a plurality is one or more, the meaning of a plurality is two or more, and the above, below, exceeding, etc. are understood as excluding the present numbers, and the above, below, within, etc. are understood as including the present numbers. If the first and second are described for the purpose of distinguishing technical features, they are not to be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated or implicitly indicating the precedence of the technical features indicated.
In the description of the present invention, unless otherwise explicitly limited, terms such as arrangement, installation, connection and the like should be understood in a broad sense, and those skilled in the art can reasonably determine the specific meanings of the above terms in the present invention in combination with the specific contents of the technical solutions.
In the description of the present invention, reference to the description of the terms "one embodiment," "some embodiments," "an illustrative embodiment," "an example," "a specific example," or "some examples," etc., means that a particular feature, mechanism, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, mechanisms, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Referring to fig. 1 and fig. 2, a detection kit 100 for screening gene mutation of an erythroid transcription factor EKLF using an HRM according to an embodiment of the present invention includes a box body 110, a cover 120, a buffer frame 130, an upstream and downstream primer pair reagent tube 140, a PCR reaction premix reagent tube 150, and a negative quality control reagent tube 160.
Referring to fig. 1, a box body 110 has a containing cavity 111; the cover 120 is used for covering the case 110 and can be opened and closed relative to the case 110; the buffer rack 130 is accommodated in the accommodating cavity 111, the height of the box body 110 is higher than that of the buffer rack 130, the buffer rack 130 forms 3 placing areas with different heights, namely a first placing area 131, a second placing area 132 and a third placing area 133, and the first placing area 131, the second placing area 132 and the third placing area 133 are respectively used for placing an upstream primer pair reagent tube 140, a downstream primer pair reagent tube 150 and a negative quality control reagent tube 160.
In the above-mentioned detect reagent box 100 who uses HRM screening erythroid transcription factor EKLF gene mutation, through setting up buffer frame 130 to the region of placing of three difference in height, respectively be used for placing upstream and downstream primer pair reagent pipe 140, PCR reaction mixes liquid reagent pipe 150 and negative quality control article reagent pipe 160 in advance, thereby integrate all reagents of screening EKLF gene mutation in a box body 110, and the high diverse in the region that different types of test solution placed, can make things convenient for medical personnel to distinguish fast and the operation of taking, thereby quick the detection of carrying out, buffer each reagent pipe through setting up buffer frame 130, the convenience is protected the reagent pipe in the transportation.
Referring to fig. 1, in an embodiment of the present invention, in order to facilitate storage and transportation of the whole detection kit 100 for screening mutation of an red transcription factor EKLF gene by using an HRM, a mounting cavity 134 is formed in the middle of a buffer frame 130, a refrigerant 170 is disposed in the mounting cavity 134, and the detection reagent is kept in a low temperature environment by disposing the refrigerant 170, so that an external ice bag is not required to be additionally provided, and the detection kit 100 for screening mutation of an red transcription factor EKLF gene by using an HRM is conveniently used.
The refrigerator 170 in this embodiment is a biological ice box, so that sufficient refrigeration performance can be ensured.
Referring to fig. 1, in an embodiment of the present invention, the buffer frame 130 includes a base 135 and a fixing seat 136, the base 135 is provided with a placing groove, the fixing seat 136 is provided at the top of the base 132, the fixing seat 133 forms each placing area, and the fixing seat 136 and the base 135 enclose to form an installation cavity 134. By arranging the buffer frame 130 in two parts, the base 135 is placed in the box body 110, the refrigerant 170 is placed in the base 135, and the fixing seat 136 is installed, so that the whole buffer frame 130 is convenient to install.
The base 135 in this embodiment is made of foam, so that the supporting strength is ensured and the buffering effect is also ensured; the fixing seat 136 is made of sponge, so that the fixing seat 136 has the effects of shock absorption, heat preservation and damage prevention after wetting.
Referring to fig. 2, in order to facilitate the placement of each reagent tube in each placement region, the first placement region 131 is provided with a first placement hole 1311 along the height direction of the cassette body 110, and the upstream and downstream primer pair reagent tubes 140 are inserted into the first placement hole 1311; the second placement area 132 is provided with a second placement hole 1321 along the height direction of the cartridge body 110, and the PCR reaction premix reagent tube 150 is inserted into the second placement hole 1321; the third placement area 133 is provided along the height direction of the cassette body 110, and the negative control material reagent tubes 160 are inserted into the third placement holes 1331, thereby facilitating the placement of the respective reagent tubes on the buffer frame 130 by providing the placement holes in the respective areas.
In this embodiment, since the reagent tubes in the respective placing regions contain different amounts of reagents, the number of placing holes formed in the first placing region 131, the second placing region 132, and the third placing region 133 may be different from each other.
Specifically, the first placing section 131 in the present embodiment is provided with 9 first placing holes 1311, the second placing section 132 is provided with 1 second placing hole 1321, and the third placing section 133 is provided with 1 third placing hole 1331.
In addition, in order to facilitate heat exchange, the reagent tubes are cooled by the refrigerator 170, and the first placing hole 1311, the second placing hole 1321, and the third placing hole 1331 are communicated with the mounting chamber 134, so that the refrigerator 170 cools the reagent in each reagent tube.
It can be understood that the first placing hole 1311, the second placing hole 1321 and the third placing hole 1331 may have a hole diameter larger than the outer diameter of the reagent tube, so as to facilitate the reagent tube to penetrate the fixing seat 136, and the reagent tube can contact the refrigerating object 170 at the bottom of the reagent tube after being inserted into the placing hole, thereby ensuring the refrigerating effect on the test solution.
Referring to fig. 1, in an embodiment of the utility model, in order to use the detection kit 100 for screening the mutation of the red transcription factor EKLF gene by using the HRM, an adhesive tape 121 is disposed on an edge of an inner surface of the cover 120, and a tear strip 122 is disposed on the cover 120, so that the cover 120 is covered on the case 110 by the adhesive tape 121, and when the detection kit 100 for screening the mutation of the red transcription factor EKLF gene by using the HRM is used, the tear strip 122 is torn off, and then the cover 120 is opened with respect to the case 110 to use the detection kit 100 for screening the mutation of the red transcription factor EKLF gene by using the HRM.
In addition, in order to facilitate the information query of the detection kit 100 for screening the gene mutation of the erythroid transcription factor EKLF by using the HRM, a two-dimensional code 123 may be further disposed on the cover 120, so that the medical staff can conveniently query the configuration information and the use instruction of the reagent. The two-dimensional code 123 in this embodiment is disposed on the inner side of the cover lift 120, and in other embodiments, may be disposed on the outer side of the cover body 120.
In this embodiment, 9 upstream and downstream primer pair reagent tubes 140 are disposed in the first placement region 131, each upstream and downstream primer pair reagent tube 140 is provided with an upstream and downstream primer pair, the 9 pairs of upstream and downstream primer pairs cover the promoter region of the EKLF gene, the exon region of the EKLF gene, and the 3' UTR region of the EKLF gene, and the concentration of the upstream and downstream primer pairs in each upstream and downstream primer pair reagent tube 140 is 10 μ M.
Specifically, 9 pairs of upstream and downstream primers were as follows:
(1) upstream and downstream primers for the promoter region of the EKLF gene: 5'-TACCCAGCACCTGGACCCTC-3', 5'-GAGGCTGTGATAGCCCCTTCG-3', respectively;
(2) the upstream and downstream primers of the exon region of the EKLF gene are respectively as follows:
one type is as follows: 5'-CTAAGGACAGAGAGGAGCCC-3', 5'-CAGCCAGCCCACCTAGAC-3', respectively;
class II-1: 5'-CCAGTGTCCACCGAACCTC-3', 5'-ATCCTCCGAACCCAAAAGCC-3', respectively;
class II-2: 5'-CGAGACTCTGGGCGCATA-3', 5'-GGAAGTGCCCTTGGTACTGA-3', respectively;
class II-3: 5'-GTACCCCGCGATGTACCC-3', 5'-CGGTCTCGGCTATCACACC-3', respectively;
class II-4: 5'-GGGGACTGCAGAGGATCCA-3', 5'-GCGCCCTTTCTCATGTCC-3', respectively;
three types are as follows: 5'-CAGACAGTGGCGCTTATGG-3', 5'-CCCCAGTCACTAGGAGAGTCC-3', respectively;
(3) the upstream and downstream primers of the 3' UTR region of the EKLF gene are respectively as follows:
one type is as follows: 5'-CATGAAGCGCCACCTTTGAGC-3', 5'-TCTCACTGGGTTTGCACGACA-3', respectively;
the second type is as follows: 5'-GAGCCACACAGAGATGTCCAAAC-3', 5'-TTACAGCCTCCTGCCATCTTCC-3', respectively;
the total volume of the PCR reaction premix placed in the PCR reaction premix reagent tube 150 in this embodiment is 1mL, and the components of the PCR reaction premix include 10 XPCR buffer, 2.5nM dNTPs, 5U/. mu.L Taq DNA polymerase, 1 XPLC Green, 5M Betain, deionized water and DMSO.
The detection kit 100 for screening the gene mutation of the red transcription factor EKLF by using the HRM in this embodiment includes the following steps:
taking EKLF gene promoter region mutation screening as an example;
step 1-preparation of DNA of a sample to be tested: collecting peripheral blood samples of a detected person, and extracting sample DNA by adopting a column method;
step 2, subpackaging the reaction solution: mixing the upstream and downstream primers in the EKLF gene promoter region with the PCR reaction premix, and distributing the mixture into a 96-well PCR plate of Bio-Rad, wherein each well comprises 0.6 mu l of upstream and downstream primer pairs and 8.4 mu l of PCR reaction premix;
step 3-adding the DNA of the sample to be detected: adding 1 mul of negative quality control materials into the front three holes of a 96-hole PCR plate respectively, adding 1 mul of different sample DNA to be detected into the other 96 holes, then carrying out instantaneous centrifugation on the 96-hole plate, carrying out liquid sealing by using liquid paraffin after ensuring that the DNA is mixed into reaction liquid, and finally covering the upper part of the 96-hole PCR plate by using tinfoil;
step 4-PCR reaction: pre-denaturation at-95 ℃ for 5 minutes on a PCR instrument according to specific cycle conditions; 45 cycles (melting: 95 ℃ for 30 seconds, annealing: 63-68 ℃ for 30 seconds, and extension: 72 ℃ for 30 seconds); denaturation: denaturation at 95 ℃ for 1 min, and final incubation at 4 ℃;
step 5-HRM analysis: after completion of PCR amplification, fluorescence was detected on a high resolution melting curve analyzer (LightScanner HR I96) with a Start temperature "Start Temp" set to 55 ℃, an End temperature "End Temp" set to 98 ℃, and a standby temperature "Hold Temp" set to 42 ℃;
step 6, interpretation of results: selecting a positive sample according to a melting curve scanned by the HRM instrument;
step 7-sequencing verification: and (3) sucking the PCR product of the positive sample, sending the PCR product to a sequencing company for Sanger sequencing verification, and judging the mutation point according to a sequencing peak diagram.
The detection kit 100 for screening the gene mutation of the erythroid transcription factor EKLF by using the HRM has the following advantages: (1) when EKLF mutation is screened, a sequence specific probe is not needed, the restriction of base sites is avoided, and known or unknown mutation and SNP sites are detected at the same time; (2) after liquid sealing is carried out by using liquid paraffin, electrophoresis or PCR products do not need to be transferred, and the whole process is operated in a closed tube manner, so that cross contamination is avoided; (3) the kit has specificity and accuracy, higher flux and simple and convenient operation; (4) 96 amplicons of samples can be detected and scanned at one time, the detection process only needs 60-90 minutes, compared with the existing nucleic acid Sanger sequencing method, the time required by detection is greatly reduced, and the detection efficiency is improved; (5) the positive and negative quality control products are adopted as the quality control of the reagent, so that the quality of the reagent can be strictly controlled; only the samples with positive mutation screening are subjected to Sanger sequencing verification, so that the detection efficiency is improved, the cost of detection reagents and labor cost are greatly reduced, and the method is suitable for large-scale population screening.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention. Furthermore, the embodiments of the present invention and the features of the embodiments may be combined with each other without conflict.
Claims (9)
1. A detection kit for screening gene mutation of an erythroid transcription factor EKLF by using HRM is characterized by comprising:
the box body is provided with an accommodating cavity;
the cover body is used for sealing the box body and can be opened and closed relative to the box body;
the buffer frame, accept in accept the intracavity, just the height of box body is higher than the height of buffer frame, the buffer frame forms 3 high diverse and places the district, is first to place the district, the second is placed the district and the third is placed the district respectively, first place the district the second is placed the district with the third is placed the district and is used for placing upstream and downstream primer pair reagent pipe, PCR reaction premix liquid reagent pipe and negative quality control article reagent pipe respectively.
2. The detection kit for screening gene mutation of red transcription factor EKLF by HRM as claimed in claim 1, comprising 9 upstream and downstream primer pair reagent tubes, each of which is provided with an upstream and a downstream primer pair.
3. The detection kit for screening gene mutation of red transcription factor EKLF (acute renal failure) by using HRM as claimed in claim 2, wherein the concentration of the upstream and downstream primer pair is 10 μ M.
4. The detection kit for screening the gene mutation of the erythroid transcription factor EKLF by using the HRM as claimed in claim 1, wherein a mounting cavity is formed in the middle of the buffer frame, and a refrigerant is disposed in the mounting cavity.
5. The detection kit for screening the gene mutation of the erythroid transcription factor EKLF by using the HRM as claimed in claim 4, wherein the first placement region is provided with a first placement hole along the height direction of the kit body, and the upstream and downstream primer pair reagent tubes are inserted into the first placement hole; the second placing area is provided with a second placing hole along the height direction of the box body, and the PCR reaction premixed liquid reagent tube is inserted into the second placing hole; and a third placing hole is formed in the third placing area along the height direction of the box body, and the negative quality control product reagent tube is inserted into the third placing hole.
6. The kit as claimed in claim 5, wherein the first, second and third holes are all in communication with the mounting cavity.
7. The detection kit for screening gene mutation of erythroid transcription factor EKLF (extended high frequency fluorescence spectroscopy) by using HRM (high resolution melting) as claimed in claim 4, wherein the buffer frame comprises a base and a fixed seat, the base is provided with a placing groove, the fixed seat is arranged on the top of the base, the fixed seat forms each placing area, and the fixed seat and the base are enclosed to form the installation cavity.
8. The detection kit for screening the gene mutation of the red transcription factor EKLF by using the HRM as claimed in claim 7, wherein the base is made of foam, and the fixing base is made of sponge.
9. The detection kit for screening the gene mutation of the erythroid transcription factor EKLF using the HRM as claimed in claim 1, wherein an adhesive tape is disposed on an inner surface edge of the cover, and a tear strip is disposed on the cover.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202122354519.8U CN216469406U (en) | 2021-09-27 | 2021-09-27 | Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202122354519.8U CN216469406U (en) | 2021-09-27 | 2021-09-27 | Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN216469406U true CN216469406U (en) | 2022-05-10 |
Family
ID=81437694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202122354519.8U Expired - Fee Related CN216469406U (en) | 2021-09-27 | 2021-09-27 | Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN216469406U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621700A (en) * | 2021-09-27 | 2021-11-09 | 广东省妇幼保健院 | Method for screening gene mutation of erythroid transcription factor EKLF and application thereof |
-
2021
- 2021-09-27 CN CN202122354519.8U patent/CN216469406U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621700A (en) * | 2021-09-27 | 2021-11-09 | 广东省妇幼保健院 | Method for screening gene mutation of erythroid transcription factor EKLF and application thereof |
| CN113621700B (en) * | 2021-09-27 | 2023-10-27 | 广东省妇幼保健院 | Method for screening red transcription factor EKLF gene mutation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lay et al. | Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR | |
| EP1117834B1 (en) | Multiplex genotyping using fluorescent hybridization probes | |
| Donohoe et al. | Rapid single-tube screening of the C282Y hemochromatosis mutation by real-time multiplex allele-specific PCR without fluorescent probes | |
| AU695606B2 (en) | A DNA meltometer and methods of use thereof | |
| US20200292565A1 (en) | Automated nucleic acid sample preparation, detection, and analysis system | |
| CN104602817B (en) | For performing the devices, systems, and methods of hot melt analysis and amplification | |
| CN216469406U (en) | Detection kit for screening gene mutation of erythroid transcription factor EKLF (extended cytokine-like protein) by using HRM (high-resolution melting) | |
| US10253366B2 (en) | Discrimination of blood type variants | |
| Qian et al. | Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform | |
| US8551737B2 (en) | Method for analysing amplified nucleic acids | |
| CN111154860A (en) | Primer, probe composition, kit and method for detecting SLCO1B1 and APOE gene polymorphism | |
| Borgbo et al. | Genotyping common FSHR polymorphisms based on competitive amplification of differentially melting amplicons (CADMA). | |
| EP2450443A1 (en) | Target sequence amplification method, polymorphism detection method, and reagents for use in the methods | |
| Sirdah | Superparamagnetic-bead based method: an effective DNA extraction from dried blood spots (DBS) for diagnostic PCR | |
| CN111154862A (en) | Primer, probe composition, kit and method for detecting ABCB1 and LDLR gene polymorphism | |
| CN110982895A (en) | Primer group and kit for detecting human erythrocyte ABO blood type genotyping and application | |
| Chiu et al. | Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics Recent Developments in Fetal DNA in Maternal Plasma | |
| Mithraprabhu et al. | Analysis of circulating tumor DNA | |
| JP2007175003A (en) | Genetic analyzer | |
| WO2006106867A1 (en) | Apparatus for determining gene polymorphism | |
| US20060147921A1 (en) | Method of amplifying nucleic acid and apparatus therefor | |
| Jiang et al. | Genotyping Parkinson disease-associated mitochondrial polymorphisms | |
| US20120021413A1 (en) | Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor | |
| Traeger-Synodinos et al. | Rapid detection of fetal Mendelian disorders: thalassemia and sickle cell syndromes | |
| RU2352641C1 (en) | Method of diagnosing heredotary predisposition to thrombophilia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220510 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |